Severe Uncontrolled Asthma

SAN DIEGO — Greenhouse gas emissions associated with severe asthma care are a substantial portion of the health care carbon footprint in the U.K., according to a poster presented at the American Thoracic Society International Conference.

Tezspire reduced asthma exacerbations across all seasons, regardless of sensitivities to perennial and seasonal aeroallergens, a recent study showed.

HONOLULU — Tezepelumab improved outcomes among patients with severe, uncontrolled asthma regardless of BMI, according to an abstract presented at the CHEST Annual Meeting.

Tezepelumab reduced health care utilization for asthma across all outcomes measured, as well as the severity of exacerbations that required hospitalizations, according to a study published in Annals of Allergy, Asthma & Immunology.

WASHINGTON — Children with severe uncontrolled asthma commonly have eosinophilic airway inflammation, according to data presented at the American Thoracic Society International Conference.

In patients with severe, uncontrolled asthma, tezepelumab reduced the rate of asthma exacerbations and was tolerated for up to 2 years, according to an extension study published in The Lancet Respiratory Medicine.

Tezepelumab treatment reduced mucus scores, which correlated with lung function improvement, among patients with moderate to severe uncontrolled asthma, researchers reported at the European Respiratory Society International Congress.

SAN FRANCISCO — A higher proportion of patients with severe, uncontrolled asthma treated with tezepelumab achieved on-treatment clinical response compared with patients treated with placebo, according to a new NAVIGATOR study analysis.

Tezepelumab reduced exacerbations, improved lung function and reduced biomarkers in patients with severe, uncontrolled asthma with or without perennial allergies, according to a post hoc analysis of the phase 2b PATHWAY study.